<DOC>
	<DOCNO>NCT00003681</DOCNO>
	<brief_summary>RATIONALE : Amifostine may improve blood count patient myelodysplastic syndrome . Epoetin alfa may stimulate red blood cell production effective treatment anemia patient myelodysplastic syndrome . PURPOSE : Phase II trial study effectiveness amifostine without epoetin alfa treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Amifostine With Without Epoetin Alfa Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Compare effect amifostine alone combination epoetin alfa bone marrow progenitor cell number blast cell , blood leukocyte count , reticulocyte , hemoglobin level , platelet count well peripheral blood bone marrow blast cell count patient myelodysplastic syndrome low risk develop acute leukemia . II . Determine partial complete response duration response patient population . III . Characterize subjective objective toxicity amifostine patient . OUTLINE : This multicenter study . Patients receive amifostine IV 3 time per week 3 week follow 1 week rest . Response assess 2 course therapy . Treatment continue absence disease progression . Patients complete response receive 1 additional course . Patients partial response stable disease stratify 2 group : Group 1 : Patients hemoglobin least 10 g/dL without transfusion receive 2 additional course amifostine alone . Group 2 : Patients hemoglobin less 10 g/dL , transfusion dependent , receive 2 additional course amifostine combination epoetin alfa subcutaneously 3 time per week . Both group reevaluate 2 additional course . Treatment may continue discretion treat physician . Patients follow every 3 month . PROJECTED ACCRUAL : A total 27-50 patient accrue study within 1.3 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis good intermediate prognosis myelodysplasia one follow type : Refractory anemia Refractory anemia ring sideroblast Refractory anemia excess blast great 10 % bone marrow blast No complex abnormality involvement chromosome 7 PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Hemoglobin great 10 g/dL OR Transfusion requirement least 2 pack RBC per month AND/OR Platelet count great 50,000/mm3 AND/OR Neutrophil count great 1,000/mm3 Hepatic : Bilirubin great 2.5 time upper limit normal ( ULN ) SGPT/ALT great 2.5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No severe cardiac dysfunction ( CTCNCIC grade III IV ) Pulmonary : No severe pulmonary dysfunction Neurologic : No history CNS disturbances Other : No current recent history allergies No nonmalignant systemic disease Not pregnant nursing No active uncontrolled infection Must cytogenetics do within past 4 month PRIOR CONCURRENT THERAPY : Biologic therapy : At least 2 month since prior growth factor biological response modifier myelodysplastic syndrome except supportive care No concurrent hematopoietic growth factor Chemotherapy : At least 2 month since prior chemotherapy myelodysplastic syndrome Endocrine therapy : No concurrent glucocorticoids No concurrent androgens Radiotherapy : Not specify Surgery : Not specify Other : No concurrent vitamin A D derivative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2000</verification_date>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>anemia</keyword>
</DOC>